Onassis Holdings, trading under OTC: ONSS, has announced the commencement of a Regulation A+ financing initiative in partnership with Dalmore Group. This arrangement enables the biotech-focused holding company to secure up to $75 million in annual funding from public investors. The financing round represents a significant opportunity for Onassis to advance its research in longevity and rejuvenation technologies, particularly through epigenetic reprogramming methods.
The collaboration with Dalmore Group brings substantial expertise to the financing effort, as the firm has supported more than 270 Regulation A+ issuers since 2021. With over 16 years of industry experience, Dalmore provides comprehensive services including marketing and public relations support, marketplace syndication, and secondary trading solutions. These resources are critical for Onassis to effectively reach potential investors and maximize the financing round's success.
Onassis Holdings operates through its subsidiary, Ananda Labs, which focuses on developing innovative therapies using patented proteins designed to rejuvenate aging cells while preserving their unique characteristics. This approach to epigenetic reprogramming has potential implications for treating age-related diseases and extending human healthspan. The funding secured through this Regulation A+ offering will directly support these research and development efforts.
The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio. InvestorWire provides advanced wire-grade press release syndication services, reaching thousands of outlets and millions of social media followers. For additional details about the financing initiative, readers can access the full press release at https://ibn.fm/s9HOQ. More information about Onassis Holdings and its biotechnology focus is available at https://www.onassis-holdings.com/.
This financing round is important because it demonstrates growing investor interest in biotechnology companies working on aging and rejuvenation technologies. Regulation A+ offerings provide smaller companies like Onassis Holdings with access to public capital markets without the extensive regulatory requirements of traditional public offerings. The success of this financing could accelerate the development of epigenetic therapies that address fundamental aging processes, potentially leading to new treatments for age-related conditions that affect millions worldwide.
